TABLE 1.

Real Option Value

	First-line ipilimumab		Second-line ipilimumab
	No subsequent CIT	Subsequent CIT	No subsequent CIT	Subsequent CIT
Proportion of patients in each cohort, %a	77.6 (236/304)	22.4 (68/304)	80.9 (72/89)	19.1 (17/89)
Mean overall survival, months	21.7	38.3	13.9	38.9
ROV (survival, months)	22.4% × (38.3 − 21.7) = 3.7		19.1% × (38.9 − 13.9) = 4.8
ROV (% of conventional survival gain)	3.7 ÷ (21.7 − 11.1) × 100 = 34.9		4.8 ÷ (13.9 − 5.4) × 100 = 56.5
Proportion of patients receiving first-line/second-line ipilimumab, %	77.4		22.6
Overall ROV	3.9 months

^aUsing the number in each cohort divided by total number receiving first-line or second-line ipilimumab.

CIT = cancer immunotherapy; ROV = real option value.